I'm going to hold until some big pharma buys them after the June presentation:
. A final presentation will report data from a study of tesetaxel plus capecitabine (Xeloda®; Hoffmann La Roche, Inc.), a drug combination that will be featured in Genta's late-stage clinical trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.